02 Nov 2017

Incentives, IP and smaller companies – the story of TiGenix

Download the Case Story in PDF format here How TiGenix wants to change patients’ lives by improving health outcomes TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced Belgian...

Read more
24 Oct 2017

Incentives, IP and smaller companies – the story of ProAxsis

Download the Case Story in PDF format here How ProAxsis helps to change patients’ lives by improving diagnostics ProAxsis Limited is a spin out from Queen’s University of Belf...

Read more
18 Oct 2017

Incentives, IP and smaller companies – the story of CureVac

Download the Case Story in PDF format here How CureVac helps to change patients’ lives CureVac, a biopharmaceutical company headquartered in Tübingen, Germany, has grown from three orig...

Read more
01 Oct 2017

Eduardo Bravo discusses the importance of pharmaceutical incentives to SMEs in the Parliament Magazine

An article written by Eduardo Bravo, CEO TiGenix and EBE President on 28 September 2017, and published in the Parliament Magazine  Incentives, particularly intellectual property (IP) protection,...

Read more
28 Aug 2017

Escher “Pharmacovigilance of Biologics” Project – Outcome

The 2015 Escher project ‘Pharmacovigilance of Biologics’ investigated how adverse reactions to biologic medicines are recorded in different settings in the Netherlands, aiming to understand ho...

Read more
02 Jun 2017

Reinventing the European Advanced Therapies Sector: An Interview with Eduardo Bravo

In this interview with Eduardo Bravo, CEO of TiGenix and President of the Board of the European Biopharmaceutical Enterprises (EBE), we discuss the increasing challenge for EU biotech companies to commercialise at home, and the accelerating departure of cutting-edge European biotech start-ups through IPOs and, increasingly, mergers and acquisitions. Interview by Duane Schulthess/ ...

Read more
10 May 2017

What pricing and reimbursement policies to use for off-patent biologicals? – Results from the second EBE biological medicines policy survey

Objective: Biosimilar policies with a focus on uptake have received a lot of attention at national and regional level in the last few years. It is now 10 years since the first biosimilar was approved in the European Union, but do policies in the Member States take the differences between biological medicines and small-molecule generics into account? To map the policy landscape in Europe, European Biopharmaceutical Enterprises (EBE) has conducted a second round of its descriptive survey of pricing and reimbursement policies for off-patent biologicals....

Read more
15 Mar 2017

Biosimilar product labels in Europe: what information should they contain?

To discuss current labelling of biosimilars in Europe, the European Biopharmaceutical Enterprises (EBE) and the European Association for Bioindustries (EuropaBio) held a multi-stakeholder workshop on...

Read more
03 Aug 2016

A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products

For the past two years, representatives from eight different pharmaceutical companies which manufacture biotechnological products have been discussing visible particles. The probability of seeing a...

Read more
22 Feb 2016

EuropaBio and EBE host a multi-stakeholder debate on the labelling of biosimilar medicines

On 2 February 2016, EuropaBio, the European Association for Bio Industries, and EBE, the European Biopharmaceutical Enterprises, jointly facilitated a multi-stakeholder workshop in Brussels on the...

Read more
1 2 3 4